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Sir,
The anatomical and functional benefit of bevacizumab
in the treatment of macular edema associated with
Purtscher-like retinopathy
We read the article by Miguel et al1 regarding Purtscher’s
and Purtscher-like retinopathies with great interest. As
the authors well describe, ‘Purtscher-like retinopathy’ is
diagnosed in patients with fundus findings similar to
Purtscher’s retinopathy, without a history of trauma but
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Figure 1 Dilated fundus examination at presentation. (a) Mosaic color fundus photo OD demonstrating multiple cotton wool spots,
superficial retinal hemorrhages surrounding the optic nerve, macular edema, and scattered intraretinal hemorrhages. (b) Mosaic color
fundus photo OS demonstrating similar but milder retinal pathology.

Figure 2 Heidelberg high-definition OCT images at presentation and 3-month follow-up. (a) OD at presentation demonstrating
severe macular edema. (b) OD at 3-month follow-up with significantly improved macular edema after treatment with intravitreal
bevacizumab. (c) OS at presentation with milder macular edema. (d) OS at 3-month follow-up with resolved macular edema.

with known systemic associations.1 Current proposed
mechanisms for the underlying pathogenesis include
leukocyte aggregation by activated complement factor 5
(C5a).2 As noted by the authors’ systematic review, there
is currently no established treatment for Purtscher-like
retinopathy, although the literature consists of several
case reports of treatment with corticosteroids, without
certainty as to effect on the clinical course.1 Herein, we
report for the first time a case of Purtscher-like
retinopathy treated successfully with intravitreal
bevacizumab injection.
Case report
A 51-year-old man presented to the Retina Service at the
University of Louisville with sudden nontraumatic loss
of vision OD. The patient’s medical history included
hepatitis C, with chronic pancreatitis and cirrhosis.
Best-corrected visual acuity (BCVA) was finger counting
OD and 20/30 OS. Fundoscopy revealed cotton wool
spots and intraretinal hemorrhages surrounding normal
optic discs bilaterally (Figure 1). Optical coherence
tomography (OCT) showed macular edema more severe
on the right eye (Figure 2). Complete blood count with
differential, kidney function tests, CRP, cryoglobulin, and
amylase were normal. Serum C5a was elevated at
12.9 ng/ml (normal range 4.7–9.5 ng/ml).
The patient received an intravitreal injection of
bevacizumab (1.25 mg/0.05 ml) (Genentech, South San
Francisco, CA, USA) OU for the treatment of macular

edema. At 3-month follow-up BCVA OD improved to
20/160 with resolution of macular edema in both eyes
(Figure 2).
Comment
Purtscher-like retinopathy is an uncommon disease
associated with various conditions.3 Treatment with
corticosteroids has been proposed, but its effectiveness is
still controversial.1 This is the first case to describe the
beneficial anatomical and functional effects of intravitreal
bevacizumab for the management of macular edema
associated with Purtscher-like retinopathy. We suggest
this treatment be considered in similar cases.
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